Latest Breaking News On - Head of global development - Page 1 : comparemela.com

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

China
United-states
Josh-smiley
Harald-reinhart
Zai-lab-forward
Zai-lab
Exchange-commission
Zai-lab-limited
Head-of-global-development
Chief-operating-officer
Global-development
Infectious-diseases

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on.

Japan
Macau
Laos
Philippines
Hong-kong
Cambodia
Taiwan
New-zealand
Vietnam
Republic-of
Indonesia
Australia

Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+

Zai Lab Ltd. (ZLAB) and Innoviva Specialty Therapeutics announced Monday that China's National Medical Products Administration or NMPA has approved Zai Lab's New Drug Application for XACDURO (sulbactam-durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China.

China
Chinese
Harald-reinhart
Entasis-therapeutics-inc
China-national-medical-products-administration
Head-of-global-development
Zai-lab
Zai-lab-new-drug-application
Drug-administration
Zai-lab-ltd
More-such-health-news
World-health-organization

Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China

Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

China
Japan
Laos
Hong-kong
United-states
Shanghai
Philippines
Indonesia
Thailand
Cambodia
New-zealand
Malaysia

Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript

Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Prague
Praha
Hlavníesto
Czech-republic
China
Japan
United-states
Chinese
American
Andrew-zhu
Louise-chen
Yigal-nochomovitz